The Latest Cardiac and Vascular News
GREENWICH, Conn.–(BUSINESS WIRE)–Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer. Dr. Grant was the former Deputy Director, Division of Cardiology and Nephrology at the FDA. During his more than 20-year career at the FDA, he was responsible for […]
SAN MATEO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the completion of enrollment in its 250-patient SUMMIT MAX clinical trial (NCT05018650) evaluating the safety and effectiveness of its HiPoint™ 88 […]
BORDEAUX, France–(BUSINESS WIRE)–FineHeart S.A., a clinical stage medical device company developing innovative devices for cardiology today announced the successful filing of six new international patents for its FlowMaker®, a fully implantable device for the treatment of patients with advanced heart failure. These patents increase the company’s solid international portfolio to 147 […]
HERZLIYA, Israel, Feb. 20, 2024 /PRNewswire/ — X-trodes, a bio-convergence company bringing wireless monitoring solutions to the home environment, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for X-trodes’ Smart Skin solution (marketed as X-trodes System M), a new wireless wearable technology for advanced electrophysiological monitoring. X-trodes’ Smart Skin is comprised of customizable dry-printed […]
GOLD COAST, Australia & HUNTINGTON BEACH, Calif.–(BUSINESS WIRE)–BiVACOR®, a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements. Led by Monash […]
WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, today announced a Series C Financing close in excess of $30M. U.S. Venture Partners (USVP), led the round. Participation included new investor Blue Ridge Medical, LLC and existing investors, including Sectoral Asset Management. “We are pleased with […]
BERLIN–(BUSINESS WIRE)–Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT). The results of this study might provide evidence of anti-α2ap antibody’s potential as a treatment option in indications of high […]
MENLO PARK, Calif., Feb. 20, 2024 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”), a pioneering medical device company at the forefront of advancing clot removal technologies for venous thromboembolism (VTE), proudly announces the enrollment and treatment of the first patient in the…
Westport, CT, Feb. 20, 2024 (GLOBE NEWSWIRE) — — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company, today announced that it has terminated a significant number of its employees and expects to substantially reduce business operations. About BioSig Technologies, Inc. BioSig Technologies is a medical […]
ST. LOUIS, Feb. 20, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 fourth quarter and full year ended December 31, 2023 on Monday, March 4, 2024 at […]
